Jon Chatzkel, MD

Dr. Chatzkel is a clinical investigator with a research focus on novel therapeutic strategies for genitourinary cancers. His work explores novel combinations involving immune checkpoint inhibitors as well as antibody-drug conjugates and other targeted therapies. He is interested in the use of biomarkers to guide therapy -- particularly the use of circulating tumor DNA to evaluate for the presence of minimal residual disease and to personalize anti-cancer therapy.

Associations

• Genitourinary Oncology
• Immuno-Oncology Program

- Evaluation of novel combinations involving immunotherapy. For example, I have served as a site PI in trials combining the VEGFR-TKI zanzalintinib and nivolumab (in patients with kidney cancer) and enfortumab vedotin and pembrolizumab (in patients with urothelial cancer). I also was co-principal investigator in a study of atezolizumab plus tivozanib in immunologically cold tumors. - Evaluation of the use of anti-body drug conjugates, particularly in bladder cancer, and particularly following the development of resistance to enfortumab vedotin. - Bladder sparing approaches in patients with muscle invasive bladder cancer. - The use of biomarkers such as circulating tumor DNA to guide adjuvant therapy in bladder and/or kidney cancer. - Novel radioligand therapies. - The implementation of novel educational interventions for hematology/oncology fellows, such as a faculty-developed spaced repetition program.

Clinical Trial 21636
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Bempegaldesleukin (); Ipilimumab (); Midazolam (); NKTR-214 (Bempegaldesleukin); Nivolumab (Opdivo); Prednisone or Prednisolone (); Relatlimab (); Taxotere (docetaxel); Warfarin (); XL092 (); Yervoy (Ipilimumab); Zanzalintinib (); caffeine (); coumadin (Warfarin); docetaxel (); omeprazole (Prilosec)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Johnson JS, Miller JW, Hatoum F, Schell MJ, Yu X, Roman Souza G, Mizelle S, Gullapalli K, Fazili A, Jain R, Chatzkel J, Cen L, Dhillon J, Cubitt C, Yao J, Whiting J, Li J, Swank J, Jameel G, Zhang J, Wang X, Spiess PE, Fishman M, Chahoud J. Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. Nat Commun. 2026 May.17(1). Pubmedid: 42185255.
• Aydogdu C, Bukavina L, Cheng L, Al-Ahmadie HA, Alhalabi O, Brown JR, Lopez-Beltran A, Grivas P, Hwang C, Grass GD, Kamat AM, Chatzkel J, Mian O, Necchi A, Ross J, Apolo AB, Spiess PE, Li R. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. 2026 Jun. Pubmedid: 42362411. Pmcid: PMC13336308.
• Mora-Garijo B, Rahman S, Xu H, Chatzkel J, Grass GD, Spiess PE, Li R. Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications. Cancers (Basel). 2026 Jul.18(13). Pubmedid: 42449716. Pmcid: PMC13359999.
• Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul.395(4):338-348. Pubmedid: 42485627.
• Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2026 Jan.12(1):38-40. Pubmedid: 40716995.
• Hou A, Mathavan A, Mathavan A, Chatzkel JA. Near-complete resolution of tumour thrombus in a patient with advanced non-seminomatous germ cell tumour: a multidisciplinary approach without surgical intervention. BMJ Case Rep. 2025 Jul.18(7). Pubmedid: 40617596.
• Lin RY, Shen S, Donabedian PL, Kiani C, Kresak JL, Chatzkel JA, Dakhoul L. Cecal Metastasis of Clear Cell Renal Cell Carcinoma After Previous Nephrectomy. ACG Case Rep J. 2024 May.11(5):e01352. Pubmedid: 38706450. Pmcid: PMC11068133.
• Chatzkel J, Fishman M, Ramnaraign B, O'Malley P, Sonpavde GP. Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic. Res Rep Urol. 2024 Jul.16:161-176. Pubmedid: 39072353. Pmcid: PMC11282163.
• George TJ, Lee JH, DeRemer DL, Hosein PJ, Staal S, Markham MJ, Jones D, Daily KC, Chatzkel JA, Ramnaraign BH, Close JL, Ezenwajiaku N, Murphy MC, Allegra CJ, Rogers S, Zhang Z, Li D, Srinivasan G, Shaheen M, Hromas R. Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms. JCO Precis Oncol. 2024 Dec.8:e2400406. Pubmedid: 39626160. Pmcid: PMC11616782.
• Scarton L, Nelson T, Jo A, O'Neal LJ, Yao Y, Huggins S, Legaspi AB, McClaren MJ, Cabassa JS, Burgos Melendez JM, Munoz-Pena JM, Markham MJ, Murphy MC, Chatzkel JA, Rogers S, George TJ. A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study. Cancer Med. 2023 Jun.12(11):12874-12880. Pubmedid: 37212484. Pmcid: PMC10278510.
• Ramnaraign BH, Lee JH, Ali A, Rogers SC, Fabregas JC, Thomas RM, Allegra CJ, Sahin I, DeRemer DL, George TJ, Chatzkel JA. Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial. Future Oncol. 2022 Nov. Pubmedid: 36399037.
• Chatzkel J, Schell MJ, Chahoud J, Zhang J, Jain R, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clin Genitourin Cancer. 2022 Jun.20(3):252-259. Pubmedid: 35249821.
• Chatzkel J, Ramnaraign B, Sonpavde G. Tivozanib for the treatment of advanced renal cell carcinoma. Expert Opin Pharmacother. 2022 Jul.23(10):1135-1142. Pubmedid: 35848061.
• Miyagi H, Kwenda E, Ramnaraign BH, Chatzkel JA, Brisbane WG, O'Malley P, Crispen PL. Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Cancers (Basel). 2022 Dec.15(1). Pubmedid: 36612164. Pmcid: PMC9817944.
• Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, Zhang W. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers (Basel). 2021 Nov.13(22). Pubmedid: 34831009. Pmcid: PMC8616149.
• Ramnaraign BH, Chatzkel JA, Al-Mansour ZA, Rogers S, Jones D, DeRemer D, George TJ. Immunotherapy Management in Special Cancer Patient Populations. JCO Oncol Pract. 2021 May.17(5):240-245. Pubmedid: 33710933.
• Chatzkel J, Mocha J, Smith J, Zhou JM, Kim Y, El-Haddad G, Zhang J. Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients. Future Sci OA. 2019 Dec.6(1):FSO437. Pubmedid: 31915536. Pmcid: PMC6920735.
• Chatzkel J, Lewis JS, Ley JC, Wildes TM, Thorstad W, Gay H, Daly M, Jackson R, Rich J, Paniello R, Nussenbaum B, Liu J, Siegel BA, Dehdashti F, Adkins D. Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head Neck Pathol. 2017 Sep.11(3):338-345. Pubmedid: 28025779. Pmcid: PMC5550393.
• Miller WT, Chatzkel J, Hewitt MG. Expiratory air trapping on thoracic computed tomography. A diagnostic subclassification. Ann Am Thorac Soc. 2014 Jul.11(6):874-881. Pubmedid: 24956379.
• Vossough A, Ziai P, Chatzkel JA. Red nucleus degeneration in hypertrophic olivary degeneration after pediatric posterior fossa tumor resection: use of susceptibility-weighted imaging (SWI). Pediatr Radiol. 2012 Apr.42(4):481-485. Pubmedid: 22218736.